Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung

Sun, Ning; Edgington, Thomas D.; Carpentier, Carmen L.; McAfee, William M.; Terry, Roger; Bateman, Joseph R.

doi:10.1002/1097-0142(19831101)52:9<1632::aid-cncr2820520915>3.0.co;2-q

Cancer

1983

DOI: 10.1002/1097-0142(19831101)52:9<1632::aid-cncr2820520915>3.0.co;2-q

|View full text |Cite

Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung

Ning Sun

Thomas D. Edgington

Carmen L. Carpentier

et al.

Abstract: Antisera to carcinoembryonic antigen (CEA), to a physicochemical subset of CEA, namely CEA‐S, and to nonspecific cross‐reacting antigen (NCA) were used for the immunohistochemical localization of these antigens in human bronchogenic carcinomas using a triple layer immunoperoxidase technique. The study is based on an analysis of tumors from 130 patients. CEA, CEA‐S, and NCA were all identified in the membrane and/or cytoplasm of neoplastic cells, and a good correlation between the antigens was observed in a maj… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1990

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 33 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemistry also revealed an increase in carcinoembryonic antigen content of the ras-infected cells (Fig. 4 A and B), consistent with the higher levels of this marker in non-SCLC vs. SCLC tumors in patients (44). Altered keratin expression, suggesting conversion to non-SCLC (45), was also found in v-Ha-ras-infected variant cells (Fig.…”

supporting

confidence: 71%

v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Mabry

Nakagawa

Nelkin

et al. 1988

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) manifests a range of phenotypes in culture that may be important in understanding its relationship to non-SCLCs and to tumor progression events in patients. Most SCLC-derived cell lines, termed "classic" SCLC lines, have properties similar to SCLC tumors in patients, including high expression of neuroendocrine markers and low c-myc oncogene expression. A significant number of SCLC lines characterized as "biochemical or morphologic variant" SCLC lines have decreased levels of endocrine differentiation markers associated with increased proliferative indices, amplification of the c-myc oncogene, and growth patterns and biochemical markers more typical of non-SCLCs. To delineate further the relationships between these phenotypes and the molecular events involved, we have inserted the v-Ha-ras gene in SCLC cell lines with (biochemical variant) and without (classic) an amplified c-myc gene. These two SCLC subtypes had markedly different phenotypic responses to similar levels of expression of v-Ha-ras RNA. No biochemical or morphologic changes were observed in classic SCLC cells. In contrast, in biochemical variant SCLC cells, v-Ha-ras expression induced features typical of large cell undifferentiated lung carcinoma, including adherent monolayer growth patterns, increased cloning efficiency, increased levels of non-SCLC cell markers, ultrastructural characteristics, and an acquired resistance to polyamine depletion typical of large cell carcinoma, but not SCLC, in vitro. Expression of v-Ha-ras in biochemical variant SCLC cells directly demonstrates that important transitions can occur between phenotypes of human lung cancer cells and that these may play a critical role in tumor progression events in patients. The finding provide a model system to study molecular events involved in tumor progression steps within a series of related tumor types.

show abstract

supporting

confidence: 71%

v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Mabry

Nakagawa

Nelkin

et al. 1988

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy

Shinkai

Saijo

Tominaga

et al. 1986

Cancer

View full text Add to dashboard Cite

The plasma carcinoembryonic antigen (CEA) levels in 243 patients with untreated advanced lung cancer were studied to assess their value for prognosis and for indicating the effectiveness of chemotherapy. Of patients with adenocarcinoma, small cell carcinoma, squamous cell carcinoma, and large cell carcinoma, 43%, 24%, 7%, and 13%, respectively, had elevated CEA levels of 20 ng/ml or greater before treatment. Pretreatment CEA levels were elevated to above 20 ng/ml for 38% of 163 patients with extensive disease and for 22% of 80 patients with limited disease (P less than 0.02). In patients with adenocarcinoma of the lung, the pretreatment CEA levels were not correlated with response to chemotherapy and patients' survival. Serial measurement of plasma CEA was a useful noninvasive technique for monitoring the response to chemotherapy in patients whose pretreatment levels were 20 ng/ml or higher. All of 18 patients with complete or partial responses and 5 of 6 patients with minor responses showed greater than 36% decrease in the CEA level compared with the pretreatment level. In all of nine patients with progressive disease, the CEA levels increased after chemotherapy. Therefore, an increase of greater than 36% beyond the baseline level was a useful guideline criterion for a significant change for determination of tumor response to chemotherapy, although 41% of 22 patients with stable disease exceeded the pretreatment level by 36% or more in either direction (mean percent change +/- standard deviation, -4.1% +/- 52.2%), and 4 of 9 patients with progressive disease did not have levels greater than 36% above the baseline levels.

show abstract

Exophytic endobronchial epidermoid carcinoma

Dulmet-Brender

Jaubert²,

Huchon³

1986

Cancer

View full text Add to dashboard Cite

Exophytic endobronchial epidermoïd carcinoma is a rare clinical entity. The authors describe and systematically analyzed 34 cases, collected during 35 years. There was a preponderance of male patients; the mean age at presentation was 58 years. The tumors were nearly always at the T1N0 stage, and their prognosis was not better than that for other Stage I bronchogenic carcinomas. The findings suggest that they are a special subvariety of bronchogenic carcinoma, rather than tumor detected at an early stage.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung

Cited by 33 publications

References 19 publications

v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy

Exophytic endobronchial epidermoid carcinoma

Contact Info

Product

Resources

About